News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Clinical

Latest News

July 28th 2016

Combining Local Peripheral Treatment With Ipilimumab Doubles Survival in Melanoma

By Surabhi Dangi-Garimella, PhD

A new study has found that combining ipilimumab with local peripheral treatments such as radiotherapy or electrochemotherapy can significantly better survival in patients with melanoma.

Critical Elimination of State Psychiatric Beds Continues at Great Human Cost

By Jackie Syrop

The Value of Patient Assistance Programs

Do Accelerated Review and Narrow Indications Influence Payer Decisions?

Clinical Pathways

Latest Videos

Daratumumab's Potential as Frontline Therapy for MM

Daratumumab's Potential as Frontline Therapy for MM

Frontline Treatment Options for Multiple Myeloma

Frontline Treatment Options for Multiple Myeloma

Considerations for Newly Diagnosed Multiple Myeloma

Considerations for Newly Diagnosed Multiple Myeloma

Increasingly Improved Outcomes for Multiple Myeloma

Increasingly Improved Outcomes for Multiple Myeloma

Treating Multiple Myeloma Through Multiple Relapses

Treating Multiple Myeloma Through Multiple Relapses

Incremental Changes in Therapy at MM Relapse

Incremental Changes in Therapy at MM Relapse

Multiple Myeloma: Approaching Treatment at First Relapse

Multiple Myeloma: Approaching Treatment at First Relapse

Optimizing Treatment for MM: Transplant and Maintenance

Optimizing Treatment for MM: Transplant and Maintenance

Newly Diagnosed Multiple Myeloma: Frontline Options

Newly Diagnosed Multiple Myeloma: Frontline Options

Selecting Therapy for Newly Diagnosed Myeloma

Selecting Therapy for Newly Diagnosed Myeloma

More News

Appropriate Use of Companion Versus Complementary Diagnostics

July 28th 2016

Influence of Biomarkers in Immunotherapy Treatment Decisions

July 28th 2016

Payer Stance on Immunotherapy in Oncology Care

July 28th 2016

Importance of Patient Assistance Programs in Oncology

July 28th 2016

Do Oncologists Contemplate Patient Cost Sharing?

July 28th 2016

Value Benchmarks in Immuno-Oncology

July 28th 2016

The Unmet Need in Immuno-Oncology and New Drug Approvals

July 28th 2016

Health Plan Take on the Cancer Drug Approval Process and Surrogate Endpoints

July 28th 2016

Improving Patient Access-Rapid Approval and Patient Assistance Programs

July 28th 2016

Combination Therapies: What Works Best for Immuno-Oncology?

July 28th 2016

Payer Concerns With Including Novel Immunotherapies on Clinical Pathways

July 28th 2016

Combination Immunotherapies in Melanoma

July 28th 2016

Understanding Immunotherapy Efficacy and Safety

July 28th 2016

Clinical Pathway Consideration and Payer Decisions

July 28th 2016

Safety and Efficacy of Targeted Therapy Versus Immunotherapy in Melanoma

July 28th 2016

Clinician Concerns with Adopting Clinical Pathways

July 28th 2016

Health Plan Perspectives on Clinical Pathways

July 28th 2016

Clinical Pathways Should Keep Pace With New Data

July 28th 2016

Distinguishing Between Companion and Complementary Diagnostic Tests

July 28th 2016

Health Plan Coverage of Diagnostic Tests for PD-L1 Expression

July 28th 2016

Predictive Biomarker Testing for Immunotherapy in Melanoma

July 28th 2016

How Important Are Biomarkers for Treatment Selection in Lung Cancer?

July 28th 2016

Early Biomarkers and Coverage Decisions in Immuno-Oncology

July 28th 2016

Immunotherapy in Oncology and the Role of the PD-L1 Biomarker

July 28th 2016

Clinical Insights on Newer Immunotherapies in Lung Cancer

July 28th 2016

Trending on AJMC

CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care

Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata

Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings

Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease

Follitropin Delta Achieves Ongoing Pregnancy in 64% Under Age 35